Exagen Inc. ( XGN ) NASDAQ Global Market

Cena: 6.99 ( 3.25% )

Aktualizacja 06-26 22:00
NASDAQ Global Market
Branża: Medical - Diagnostics & Research
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Diagnostics & Research
Zatrudnienie: 174
Giełda: NASDAQ Global Market
Ilość akcji w obrocie: 47%
Ilość akcji: 17 045 800
Debiut giełdowy: 2019-09-19
WWW: https://www.exagen.com
CEO: Mr. John Aballi
Adres: 1261 Liberty Way
Siedziba: 92081 Vista
ISIN: US30068X1037
Opis firmy:

Exagen Inc. opracowuje i komercjalizuje różne produkty testowe w oparciu o technologię aktywacji uzupełniających związaną z komórką pod marką Avise w Stanach Zjednoczonych. Umożliwia reumatologom opiekę nad pacjentami poprzez diagnozę, rokowanie i monitorowanie chorób autoimmunologicznych i autoimmunologicznych, w tym toczeń rumieniowatego (SLE) i reumatoidalnego zapalenia stawów (RA). Jego produktem testowania ołowiu jest Avise CTD, który umożliwia diagnozę różnicową u pacjentów z objawami wskazującymi na różne choroby tkanki łącznej (CTD) i inne powiązane choroby z nakładającymi się objawami. Firma oferuje Avise toczeń, który mierzy aktywację układu dopełniacza poprzez ilościowo kwantyfikację poziomu C4D komórek B i erytrocytów C4D we krwi pacjenta; i Avise APS, który składa się z panelu testów autoprzeciwciał, które pomagają w diagnozowaniu i leczeniu APS. Ponadto zapewnia Avise SLE Prognostic, panel autoprzeciwciał do oceny potencjału powikłań wpływających na układ nerek, mózgu i układ sercowo -naczyniowy; Avise zapalenie naczyń AAV, które wykorzystuje panel testowy poszczególnych analitów w celu zapewnienia lekarzom wyników oceny i monitorowania przeciwciała cytoplazmatycznego antyneutrofilowego i powiązanego zapalenia naczyń; Avise Anti-Carp Test, który identyfikuje pacjentów RA z ciężką chorobą; i Avise PC4D do pomiaru C4D związanego z płytkami krwi. Ponadto firma oferuje Avise SLE Monitor, badanie krwi biomarkerów; Avise MTX, opatentowane i zatwierdzone badanie krwi; oraz Avise HCQ, badanie krwi w celu monitorowania poziomów hydroksychlorochiny. Ma umowę o współpracy badawczej i umowy licencyjnej z Instytutem Badawczym Allegheny Health Network (AHN) w celu opracowania nowych opatentowanych biomarkerów. Firma była wcześniej znana jako Exagen Diagnostics, Inc. i zmieniła nazwę na Exagen Inc. w styczniu 2019 r. Exagen Inc. został zarejestrowany w 2002 roku i ma siedzibę w Vista w Kalifornii.

Wskaźniki finansowe
Kapitalizacja (USD) 152 765 751
Aktywa: 43 605 000
Cena: 6.99
Wskaźnik Altman Z-Score: -6.9
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -8.3
Ilość akcji w obrocie: 47%
Średni wolumen: 243 417
Ilość akcji 21 854 900
Wskaźniki finansowe
Przychody TTM 55 751 000
Zobowiązania: 30 737 000
Przedział 52 tyg.: 1.71 - 7.95
Piotroski F-Score: 2
Słaby (niska jakość finansowa)
EPS: -0.8
P/E branży: 30.3
Beta: 1.346
Raport okresowy: 2025-08-04
WWW: https://www.exagen.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. John Aballi Chief Executive Officer, President & Director 931 950 1985
Mr. Kamal Adawi M.S., MBA Chief Financial Officer & Corporate Secretary 676 087 1979
Dr. Tina S. Nova Ph.D. Executive Chairman of the Board of Directors 100 875 1954
Dr. Andrew L. Concoff FACR, M.D. Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board 0 0
Dr. Michael I. Nerenberg M.D. Chief Medical Officer 0 1955
Ryan Douglas Investors Relations Officer 0 0
Wiadomości dla Exagen Inc.
Tytuł Treść Źródło Aktualizacja Link
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursuant to the full exercise of the option granted by Exagen to the underwriter in connection with its previously announced public offering of 3,350,000 shares of common stock, which closed on May 9, 2025. globenewswire.com 2025-05-09 20:05:00 Czytaj oryginał (ang.)
Exagen Inc. Prices Public Offering of Common Stock CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share. globenewswire.com 2025-05-08 12:30:00 Czytaj oryginał (ang.)
Exagen Inc. Announces Proposed Public Offering of Common Stock CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its common stock. globenewswire.com 2025-05-07 20:05:00 Czytaj oryginał (ang.)
Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript Exagen Inc. (NASDAQ:XGN ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Jeff Black - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Mark Massaro - BTIG Andrew Brackmann - William Blair Paul Knight - KeyBanc Operator Greetings, and welcome to Exagen Inc. First Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. seekingalpha.com 2025-05-05 20:51:40 Czytaj oryginał (ang.)
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates Exagen Inc. (XGN) came out with a quarterly loss of $0.20 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago. zacks.com 2025-05-05 14:10:38 Czytaj oryginał (ang.)
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent corporate updates. globenewswire.com 2025-05-05 12:00:00 Czytaj oryginał (ang.)
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors $25 Million Funded at Close to Refinance Existing Debt and Extend Maturity Additional Borrowing Capacity Provides Minimally Dilutive Growth Capital CARLSBAD, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced it has entered into an agreement with Perceptive Advisors LLC for a term loan credit facility of up to $75 million, with $25 million funded at closing to retire an existing debt facility and strengthen the balance sheet. globenewswire.com 2025-04-28 13:00:00 Czytaj oryginał (ang.)
Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability We initiate coverage on Exagen with a Buy rating, citing a promising turnaround with growing diagnostics, improved margins, and new biomarker tests for lupus and RA. Despite a rocky history, Exagen's recent momentum, modest valuation, and potential upside from new products make it an attractive long-term speculative buy. Financially, Exagen reported $55.6 million in 2024 revenue, improved margins, and expects positive adjusted EBITDA by Q4 2025, supported by new product launches. seekingalpha.com 2025-04-26 07:31:32 Czytaj oryginał (ang.)
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025 CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT). globenewswire.com 2025-04-21 20:05:00 Czytaj oryginał (ang.)
Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript Exagen Inc. (NASDAQ:XGN ) Q4 2024 Results Conference Call March 11, 2025 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Jeff Black - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Mark Massaro - BTIG Dan Brennan - TD Cowen Andrew Brackmann - William Blair Matthew Parisi - KeyBanc Operator Greetings, and welcome to Exagen Inc. Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2025-03-11 15:13:02 Czytaj oryginał (ang.)
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights Delivered record full-year total revenue and AVISE CTD average selling price Improved full-year adjusted EBITDA loss and cash use by over 40% Commercialized new biomarkers to enhance clinical utility of AVISE CTD CARLSBAD, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2024, and recent business highlights. globenewswire.com 2025-03-11 10:00:00 Czytaj oryginał (ang.)
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025 CARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2024, before the market opens on Tuesday, March 11, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 AM ET (5:30 AM PT). globenewswire.com 2025-02-25 18:05:00 Czytaj oryginał (ang.)
Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength? Exagen (XGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com 2025-02-05 09:41:12 Czytaj oryginał (ang.)
Exagen Inc. to Participate in Upcoming Investor Conferences CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences: globenewswire.com 2025-02-04 18:05:00 Czytaj oryginał (ang.)
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn CARLSBAD, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced it has received conditional approval from the New York State Department of Health for its new systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) biomarker assays, with a planned commercial launch in January 2025. globenewswire.com 2025-01-12 14:00:00 Czytaj oryginał (ang.)
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD The milestone demonstrates AVISE CTD's value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care The milestone demonstrates AVISE CTD's value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care globenewswire.com 2024-12-12 11:00:00 Czytaj oryginał (ang.)
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease globenewswire.com 2024-11-14 18:30:00 Czytaj oryginał (ang.)
Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript Exagen, Inc. (NASDAQ:XGN ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Ryan Douglas – IR John Aballi - President & CEO Jeffrey Black - CFO Conference Call Participants Mark Massaro – BTIG Daniel Brennan - TD Cowen Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Andrew Brackmann - William Blair Operator Greetings. Welcome to the Exagen Inc. Third Quarter 2024 Earnings Call. seekingalpha.com 2024-11-12 15:09:31 Czytaj oryginał (ang.)
Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates Exagen Inc. (XGN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.31 per share a year ago. zacks.com 2024-11-12 12:25:23 Czytaj oryginał (ang.)
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College of Rheumatology's (ACR) annual meeting, ACR Convergence 2024, being held November 14-19, 2024, at the Walter E. Washington Convention Center in Washington, D.C. globenewswire.com 2024-10-21 20:05:00 Czytaj oryginał (ang.)
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference CARLSBAD, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2024 Cantor Global Healthcare Conference, which takes place September 17-19, 2024, at the InterContinental Barclay Hotel in New York City. John Aballi, Exagen's President and Chief Executive Officer and Jeff Black, Exagen's Chief Financial Officer, will participate in a fireside chat on Wednesday, September 18th, at 9:45 AM ET. globenewswire.com 2024-09-04 20:05:00 Czytaj oryginał (ang.)
Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now After losing some value lately, a hammer chart pattern has been formed for Exagen (XGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. zacks.com 2024-08-29 14:55:48 Czytaj oryginał (ang.)
Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock Exagen (XGN) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices. zacks.com 2024-08-26 13:50:36 Czytaj oryginał (ang.)
Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out? Exagen (XGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com 2024-08-09 14:15:57 Czytaj oryginał (ang.)
Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen. zacks.com 2024-08-08 13:50:26 Czytaj oryginał (ang.)
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates Exagen Inc. (XGN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.28 per share a year ago. zacks.com 2024-08-05 14:10:27 Czytaj oryginał (ang.)
Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference CARLSBAD, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 44th Annual Growth Conference, which takes place August 13-15, 2024, at the InterContinental Boston Hotel in Boston, MA. John Aballi, Exagen's President and Chief Executive Officer will participate in a fireside chat on Wednesday, August 14th, at 2:30 PM ET. Interested parties may access the webcast of the presentation using a link on Exagen's website at https://investors.exagen.com/events. globenewswire.com 2024-08-02 13:00:00 Czytaj oryginał (ang.)
Exagen Appoints Jeffrey G. Black as New Chief Financial Officer CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August. globenewswire.com 2024-08-01 13:00:00 Czytaj oryginał (ang.)
Exagen to Announce Second Quarter 2024 Results on August 5, 2024 CARLSBAD, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended June 30, 2024, before the market opens on Monday, August 5, 2024. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 8:30 AM ET (5:30 AM PT). globenewswire.com 2024-07-22 13:00:00 Czytaj oryginał (ang.)
Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen. zacks.com 2024-06-13 14:34:37 Czytaj oryginał (ang.)
Time to Play 5 Top-Ranked Stocks With Rising P/E? Wall Street has been hovering around a record high level, which can trigger overvaluation concerns in some investors' minds. This is because investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio. benzinga.com 2024-06-10 17:14:50 Czytaj oryginał (ang.)
Time to Play 5 Top-Ranked Stocks With Rising P/E? Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Exagen (XGN), Health Catalyst (HCAT), CLEAR Secure (YOU) and Applied DNA Sciences (APDN). zacks.com 2024-06-10 13:05:18 Czytaj oryginał (ang.)
Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript Exagen, Inc. (NASDAQ:XGN ) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Kyle Mikson - Canaccord Genuity Dan Brennan - TD Cowen Operator Greetings, welcome to Exagen, Inc. First Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode. seekingalpha.com 2024-05-13 15:25:02 Czytaj oryginał (ang.)
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates Exagen Inc. (XGN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.44 per share a year ago. zacks.com 2024-05-13 14:10:36 Czytaj oryginał (ang.)
Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. globenewswire.com 2024-05-13 12:00:00 Czytaj oryginał (ang.)